Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

doi:10.1097/JTO.0b013e318290868f

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2013

Lindeman Neal I, Cagle Philip T, Beasley Mary Beth, Chitale Dhananjay Arun, Dacic Sanja, Giaccone Giuseppe, Jenkins Robert Brian, Kwiatkowski David J, Saldivar Juan-Sebastian, Squire Jeremy, Thunnissen Erik, Ladanyi Marc

Abstract excerpt

OBJECTIVE: To establish evidence-based recommendations for the molecular analysis of lung cancers that are that are required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed. PARTICIPANTS: Three cochairs without conflicts of interest were selected, one from each of the 3 sponsoring professional societies: College of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Evidence-Based Medicine

Share to Gene Rearrangement

Share to Patient Selection

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Share to Societies, Medical

Share to Systematic Reviews as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 23552377
DOI: 10.1097/JTO.0b013e318290868f
PMCID: PMC4159960

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.PMID 23552377Read ↗

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.Semantic proximity Read ↗

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Semantic proximity Read ↗

Molecular Testing of Lung CancersSemantic proximity Read ↗

Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Molecular testing and personalized treatment of lung cancer.Semantic proximity Read ↗

Molecular Testing in Lung Cancer: Recommendations and Update.Semantic proximity Read ↗

Molecular Pathology of Lung Cancer.Semantic proximity Read ↗

Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.Semantic proximity Read ↗

Clinical testing for molecular targets for personalized treatment in lung cancer.Semantic proximity Read ↗

[Molecular testing clinical progress for EGFR mutation and ALK rearrangement of lung cancer based on the guideline from IASLC/CAP/AMP].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.